Compare · NVO vs SKYE
NVO vs SKYE
Side-by-side comparison of Novo Nordisk A/S (NVO) and Skye Bioscience Inc. (SKYE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SKYE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $166.18B, about 23168.0x SKYE ($7.2M).
- NVO has been more active in the news (5 items in the past 4 weeks vs 4 for SKYE).
- NVO has more recent analyst coverage (25 ratings vs 8 for SKYE).
- Company
- Novo Nordisk A/S
- Skye Bioscience Inc.
- Price
- -
- -
- Market cap
- $166.18B
- $7.2M
- 1M return
- -15.30%
- -
- 1Y return
- -35.19%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 4
- Recent ratings
- 25
- 8
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SKYE
- Director Schwab Andrew J. sold $239,555 worth of shares (148,079 units at $1.62) (SEC Form 4)
- Large owner 5am Partners Vii, Llc sold $239,555 worth of shares (148,079 units at $1.62) (SEC Form 4)
- Director Schwab Andrew J. sold $64,734 worth of shares (33,892 units at $1.91) (SEC Form 4)
- Large owner 5am Partners Vii, Llc sold $64,734 worth of shares (33,892 units at $1.91) (SEC Form 4)
- SEC Form DEFA14A filed by Skye Bioscience Inc.
- Skye Bioscience Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Other Events
- SEC Form DEFA14A filed by Skye Bioscience Inc.
- Skye Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Director Schwab Andrew J. sold $140,313 worth of shares (375,840 units at $0.37) (SEC Form 4)
- Large owner 5am Partners Vii, Llc sold $140,313 worth of shares (375,840 units at $0.37) (SEC Form 4)